Tagged with access

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Austria Christa Wirthumer-Hoche, head of the Austrian Medicines and Medical Devices Agency (AGES) and chair of the European Medicines Agency (EMA) management board, discusses the role of AGES within Austria, similarities with other countries’ regulatory agencies, Austria’s potential as an innovation hub, and the possible relocation of the EMA to Vienna…

Colombia Kenneth Garcia, General Manager of Smith & Nephew Colombia, reveals his thoughts on the rising attractiveness of the Colombian market and the growing demand for higher standards of healthcare products with a strong willingness from the government and the private sector to improve its healthcare capabilities, while also discussing Smith…

Ukraine Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company under the conditions of significant changes in the pharmaceutical market and Ukrainian healthcare system.   Nobody can deny that Ukraine…

Indonesia Benoit Martineau, President Director at Sanofi Indonesia, explains the transformation of the Indonesian affiliate and reaffirms the strong commitment of Sanofi in helping the Indonesian government to successfully implement their patient access roadmap. Mr. Martineau, could you please introduce yourself to our international audience as well as your main areas…

Austria Mogens Guldberg, general manager of Novo Nordisk Austria, the Danish global powerhouse focused on innovative diabetic treatments, provides a unique insight into the obstacles associated with launching innovative products in Austria as well as the revolution required in Austria’s diabetic approach. He also highlights how specifically Novo Nordisk assists in…

Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…

Indonesia Darodjatun Sanusi, Executive Director of GP Farmasi (National Association of Local Companies in Indonesia), explains the opportunities and challenges that his members are facing as well as the future directions that the industry should take to further enhance its capabilities and continue its growth. As Executive Director of GP Farmasi,…

Colombia Francois Léger, recently appointed GM of Servier Colombia discusses his strategy to achieve the company’s ambitious growth plans to launch eight new products within the next three years. You have been appointed General Manager four months ago. Can you introduce yourself to our executive readership? Being originally from France and…

Colombia Jaime Calderon, CEO of IETS and with an extensive clinical background and deep understanding of the Colombian healthcare sector, shares IETS’ role in advancing the healthcare landscape while promoting superior standards and taking into account the concerns of the population and industry stakeholders. You were appointed CEO of IETS in…

Indonesia Christian Eberle, president director at APL, explains the challenges and opportunities within the Indonesian healthcare distribution arena as well as the company’s strategy to bring more high-quality medicines to patients over the next two years. After over two years as CEO of APL, could you provide us with an overview…

Colombia Cristhian Salamanca, executive director of the Colombia-India Chamber of Commerce and Industry discusses the ties between both countries, the important role of the chamber in attracting Indian companies to Colombia, and the ease of doing business for pharmaceutical companies in the country after obtaining INVIMA approval. Could you please provide…